menu
    • menu
    [{"orgOrder":0,"company":"Zylo Therapeutics","sponsor":"Hoth Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"HT-005 Z-PODS","moa":"Calcineurin","graph1":"Immunology","graph2":"Preclinical","graph3":"Zylo Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zylo Therapeutics \/ Zylo Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Zylo Therapeutics \/ Zylo Therapeutics"},{"orgOrder":0,"company":"Zylo Therapeutics","sponsor":"Hoth Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"HT-005 Z-PODS","moa":"Calcineurin","graph1":"Immunology","graph2":"Preclinical","graph3":"Zylo Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zylo Therapeutics \/ Zylo Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Zylo Therapeutics \/ Zylo Therapeutics"},{"orgOrder":0,"company":"Zylo Therapeutics","sponsor":"Silo Pharma","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Agreement","leadProduct":"Ketamine Hydrochloride","moa":"Glutamate [NMDA] receptor","graph1":"Musculoskeletal","graph2":"Preclinical","graph3":"Zylo Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Implant","sponsorNew":"Zylo Therapeutics \/ Zylo Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Zylo Therapeutics \/ Zylo Therapeutics"},{"orgOrder":0,"company":"Zylo Therapeutics","sponsor":"Silo Pharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Agreement","leadProduct":"Ketamine Hydrochloride","moa":"Glutamate [NMDA] receptor","graph1":"Neurology","graph2":"Undisclosed","graph3":"Zylo Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Zylo Therapeutics \/ Silo Pharma","highestDevelopmentStatusID":"1","companyTruncated":"Zylo Therapeutics \/ Silo Pharma"}]

    Find Clinical Drug Pipeline Developments & Deals by Zylo Therapeutics

    Menu

    Zylo Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Zylo Therapeutics

                            U.S.A arrow
                            AES
                            Not Confirmed

                            Zylo Therapeutics

                            U.S.A arrow
                            AES
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ketamine Hydrochloride

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Preclinical

                            Recipient : Silo Pharma

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Psychedelics Company Silo Pharma Working on Time-Release and Dosage Ketamine Implant and Topical, Hoping to De...

                            Details : The agreement aims to create a time-release ketamine implant, SP-26, which blocks the activity of the N-methyl-D-aspartate receptor (NMDAR), to treat fibromyalgia and other chronic pain conditions.

                            Product Name : Undisclosed

                            Product Type : Controlled Substance

                            Upfront Cash : Undisclosed

                            June 23, 2023

                            Lead Product(s) : Ketamine Hydrochloride

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Preclinical

                            Recipient : Silo Pharma

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Zylo Therapeutics

                            U.S.A arrow
                            AES
                            Not Confirmed

                            Zylo Therapeutics

                            U.S.A arrow
                            AES
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ketamine Hydrochloride

                            Therapeutic Area : Neurology

                            Study Phase : Undisclosed

                            Sponsor : Silo Pharma

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Silo Pharma and Zylo Enter Into Joint Venture Agreement to Focus on the Development of Ketamine using ZTI’s ...

                            Details : The joint venture will initially explore the clinical development of ketamine using ZTI’s Z-pod technology, but also provides for Silo Pharma to obtain an exclusive option for the clinical development of psilocybin using ZTI’s Z-pod technology as wel...

                            Product Name : Undisclosed

                            Product Type : Controlled Substance

                            Upfront Cash : Undisclosed

                            April 28, 2021

                            Lead Product(s) : Ketamine Hydrochloride

                            Therapeutic Area : Neurology

                            Highest Development Status : Undisclosed

                            Sponsor : Silo Pharma

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Zylo Therapeutics

                            U.S.A arrow
                            AES
                            Not Confirmed

                            Zylo Therapeutics

                            U.S.A arrow
                            AES
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : HT-005 Z-PODS

                            Therapeutic Area : Immunology

                            Study Phase : Preclinical

                            Recipient : Hoth Therapeutics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Endocannabinoid Pathway Targeted Drug Demonstrates Proof-of-Concept Efficacy in a Cutaneous Lupus Erythematosu...

                            Details : Results from the study demonstrated that the novel HT-005 loaded Z-pods™ were effective to reduce skin plaques associated with CLE, with statistical significance demonstrated in the overall average skin score as well as individual skin scores on the he...

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            December 21, 2020

                            Lead Product(s) : HT-005 Z-PODS

                            Therapeutic Area : Immunology

                            Highest Development Status : Preclinical

                            Recipient : Hoth Therapeutics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Zylo Therapeutics

                            U.S.A arrow
                            AES
                            Not Confirmed

                            Zylo Therapeutics

                            U.S.A arrow
                            AES
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : HT-005 Z-PODS

                            Therapeutic Area : Immunology

                            Study Phase : Preclinical

                            Recipient : Hoth Therapeutics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Hoth Therapeutics Reports Positive Proof-of-Concept Preclinical Data on its Therapeutic for Cutaneous Lupus Er...

                            Details : The animal study supports that HT-005 has the potential to be an effective treatment for cutaneous manifestations of lupus, a significant unmet medical need.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            November 03, 2020

                            Lead Product(s) : HT-005 Z-PODS

                            Therapeutic Area : Immunology

                            Highest Development Status : Preclinical

                            Recipient : Hoth Therapeutics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth